Head-To-Head Review: Alpha Teknova (TKNO) and Its Competitors

Alpha Teknova (NASDAQ:TKNO – Get Rating) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its rivals? We will compare Alpha Teknova to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.

Profitability

This table compares Alpha Teknova and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-37.59%	-10.15%	-8.46%
Alpha Teknova Competitors	-2,192.62%	-1,216.29%	-29.93%

Insider & Institutional Ownership

25.5% of Alpha Teknova shares are held by institutional investors. Comparatively, 53.3% of shares of all “Diagnostic substances” companies are held by institutional investors. 10.2% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Alpha Teknova and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Teknova	$36.89 million	-$9.80 million	-8.66
Alpha Teknova Competitors	$409.34 million	$33.17 million	-89.76

Alpha Teknova’s rivals have higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for Alpha Teknova and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	0	0	4	0	3.00
Alpha Teknova Competitors	255	783	1249	40	2.46

Alpha Teknova presently has a consensus target price of $27.33, indicating a potential upside of 225.40%. As a group, “Diagnostic substances” companies have a potential upside of 88.16%. Given Alpha Teknova’s stronger consensus rating and higher possible upside, research analysts clearly believe Alpha Teknova is more favorable than its rivals.

Summary

Alpha Teknova beats its rivals on 7 of the 12 factors compared.

Alpha Teknova Company Profile (Get Rating)

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.